Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
doi: 10.1038/s41419-023-05716-0 132 KangLPHuangHJXuCChenHHHuangDHJiangZB
Sodium-glucose cotransporter 2 (SGLT2) inhibitors from natural products: discovery of next-generation antihyperglycemic agents
On March 10 th , the FDA issued guidance clarifying that 503A and 503B drug compounders must soon cease compounding semaglutide injection products[i] or risk enforcement action.[ii] This has a significant impact on compounding pharmacies as, under the Federal Food, Drug, and Cosmetic Act (the FD&C ), drug compounders are permitted to compound their own copies of a patented drug if the FDA determines it is in shortage
(2018) ( Epub 2018 Jan 2 )
US$ 20.68
US$ 29.68
US$ 28.86
US$ 29.72
US$ 23.24
